Summary by Moomoo AI
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in its latest quarterly report. However, the company has disclosed stock-based compensation for stock options, which increased from $149,153 in the nine months ended January 31, 2023, to $326,578 in the same period in 2024. Deferred tax assets have also been reported, with a net operating loss carryforwards of approximately $52 million as of January 31, 2024, up from $46 million the previous year. The company has entered into significant business development agreements, including a multi-year collaboration with Rutgers University and multiple definitive license agreements with Mount Sinai for AI cardiovascular algorithms. Heart Test Laboratories plans to submit a 510(k) FDA submission for its MyoVista device and is aiming for clearance within the 2024 calendar year. The company has also received patent allowances in various regions and has entered into financial agreements to support its operations, including an Equity Distribution Agreement with Maxim Group LLC.